Literature DB >> 17571187

Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.

Francesco Marchetti1, Kerry L Sayle, Johanne Bentley, William Clegg, Nicola J Curtin, Jane A Endicott, Bernard T Golding, Roger J Griffin, Karen Haggerty, Ross W Harrington, Veronique Mesguiche, David R Newell, Martin E M Noble, Rachel J Parsons, David J Pratt, Lan Z Wang, Ian R Hardcastle.   

Abstract

An efficient synthesis of 2-substituted O(4)-cyclohexylmethyl-5-nitroso-6-aminopyrimidines from 6-amino-2-mercaptopyrimidin-4-ol has been developed and used to prepare a range of derivatives for evaluation as inhibitors of cyclin-dependent kinase 2 (CDK2). The structure-activity relationships (SARs) are similar to those observed for the corresponding O(6)-cyclohexylmethoxypurine series with the 2-arylsulfonamide and 2-arylcarboxamide derivatives showing excellent potency. Two compounds, 4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2-hydroxyethyl)benzenesulfonamide (7q) and 4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)benzenesulfonamide (7s), were the most potent with IC50 values of 0.7 +/- 0.1 and 0.8 +/- 0.0 nM against CDK2, respectively. The SARs determined in this study are discussed with reference to the crystal structure of 4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)benzenesulfonamide (7j) bound to phosphorylated CDK2/cyclin A.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17571187     DOI: 10.1039/b703241b

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  1 in total

1.  Perhalogenated pyrimidine scaffolds. Reactions of 5-chloro-2,4,6-trifluoropyrimidine with nitrogen centred nucleophiles.

Authors:  Emma L Parks; Graham Sandford; John A Christopher; David D Miller
Journal:  Beilstein J Org Chem       Date:  2008-07-01       Impact factor: 2.883

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.